Literature DB >> 8343491

Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits.

J M Herbert1, A Tissinier, G Defreyn, J P Maffrand.   

Abstract

The possible activity of ticlopidine and its analogue clopidogrel in early atherogenesis was investigated. Incubation of rabbit platelets with the extracellular matrix produced by endothelial cells in culture induced massive platelet adherence in vitro. This phenomenon was strongly reduced when platelets were isolated from rabbits that had been treated with a single dose of clopidogrel (10 mg/kg PO) or three doses of ticlopidine (each 200 mg/kg PO) (94% and 56% inhibition of platelet adhesion, respectively). Three doses of aspirin (each 200 mg/kg PO) were ineffective. Air-drying injury of the rabbit carotid artery resulted in platelet adherence to the underlying subendothelium. This platelet accumulation on the damaged vessel wall was greatly reduced by clopidogrel: 95% (P < .001) inhibition of platelet adhesion after a single oral dose of 25 mg/kg. Ticlopidine (200 mg/kg) was also effective (71% inhibition; P < .001), whereas aspirin (100 mg/kg PO) failed to reduce platelet adhesion to the subendothelium. The effect of clopidogrel on intimal smooth muscle hyperplasia in rabbit carotid arteries subjected to air-drying endothelial injury was then investigated. After a 16-day treatment, clopidogrel (25 mg/kg per day PO) inhibited the development of intimal thickening (48% inhibition; P < .01). This effect was dose dependent and increased with the duration of the treatment. Under the same experimental conditions, ticlopidine (200 mg/kg per day PO) inhibited myointimal thickening (57%; P < .001), whereas aspirin was ineffective. These results show that clopidogrel and ticlopidine, two ADP-selective antiplatelet agents, can reduce myointimal thickening after endothelial injury. This effect can be due to the inhibition of platelet adhesion and aggregation to the exposed subendothelium.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8343491     DOI: 10.1161/01.atv.13.8.1171

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  17 in total

1.  Identifying aberrant pathways through integrated analysis of knowledge in pharmacogenomics.

Authors:  Robert Hoehndorf; Michel Dumontier; Georgios V Gkoutos
Journal:  Bioinformatics       Date:  2012-06-17       Impact factor: 6.937

2.  Invited Lectures : Overviews Purinergic signalling: past, present and future.

Authors: 
Journal:  Purinergic Signal       Date:  2006-05-15       Impact factor: 3.765

3.  Deciphering glycomics and neuroproteomic alterations in experimental traumatic brain injury: Comparative analysis of aspirin and clopidogrel treatment.

Authors:  Hussein Abou-Abbass; Hisham Bahmad; Hadi Abou-El-Hassan; Rui Zhu; Shiyue Zhou; Xue Dong; Eva Hamade; Khalil Mallah; Abir Zebian; Naify Ramadan; Stefania Mondello; Jawad Fares; Youssef Comair; Samir Atweh; Hala Darwish; Kazem Zibara; Yehia Mechref; Firas Kobeissy
Journal:  Electrophoresis       Date:  2016-03-29       Impact factor: 3.535

4.  P1,P4-dithio-P2,P3-monochloromethylene diadenosine 5',5'''-P1,P4-tetraphosphate: a novel antiplatelet agent.

Authors:  S W Chan; S J Gallo; B K Kim; M J Guo; G M Blackburn; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

5.  Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo.

Authors:  J Herbert; F Bono; J Herault; C Avril; F Dol; A Mares; P Schaeffer
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

Review 6.  Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke.

Authors:  Jesse Weinberger
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  Clopidogrel: a review of its use in the prevention of atherothrombosis.

Authors:  B Jarvis; K Simpson
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

8.  Bolus injections of novel thrombogenic site-targeted fusion proteins comprising annexin-V and Kunitz protease inhibitors attenuate intimal hyperplasia after balloon angioplasty.

Authors:  Yung-Hsin Yeh; Shang-Hung Chang; Shin-Yu Chen; Chih-Jen Wen; Fu-Chan Wei; Rui Tang; Sam Achilefu; Tze-Chein Wun; Wei-Jan Chen
Journal:  Int J Cardiol       Date:  2017-04-06       Impact factor: 4.164

Review 9.  Clopidogrel.

Authors:  A J Coukell; A Markham
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

10.  Reduced intimal hyperplasia in rabbits via medical therapy after carotid venous bypass.

Authors:  Semih Yucel; Muzaffer Bahcivan; Mehmet Kamil Gol; Behice H Erenler; Fersat Kolbakir; Hasan T Keceligil
Journal:  Tex Heart Inst J       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.